Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
8.740
+0.430 (+5.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89Bio Inc
< Previous
1
2
3
4
5
6
7
Next >
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 07, 2023
Via
Benzinga
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
Analyst Ratings for 89bio
November 28, 2023
Via
Benzinga
Analyst Expectations for 89bio's Future
October 11, 2023
Via
Benzinga
Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
December 07, 2023
U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 06, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
December 04, 2023
89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in
Via
Benzinga
Exposures
Product Safety
The Latest Analyst Ratings for 89bio
September 22, 2023
Via
Benzinga
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
December 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
November 27, 2023
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with
Via
Benzinga
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
November 27, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
November 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
November 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
October 17, 2023
From
89bio, Inc.
Via
GlobeNewswire
Why Shares of 89bio Plummeted on Tuesday
October 10, 2023
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
Via
The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
October 10, 2023
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 10, 2023
Via
Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 10, 2023
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
Via
Benzinga
Why Akero Therapeutics Stock Is Crashing Today
October 10, 2023
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
Via
The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
October 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Gain; PepsiCo Posts Upbeat Earnings
October 10, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
October 10, 2023
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.